Back to Benjamin Edwards Inc. Benjamin Edwards Inc.

CRSPCRSP

Showing 8 of 30 quarters

Position history for Benjamin Edwards Inc.Benjamin Edwards Inc.'s holdings in CRISPR Therapeutics AG

Yes. Benjamin Edwards holds 54,488 shares of CRSP (CRISPR Therapeutics), worth $3M, as of its Q2 2026 13F filing. It reduced the position by 1,018 shares (-1.8%) from Q1 2026. Benjamin Edwards has held CRSP in every 13F on record since Q1 2019, 30 quarterly filings.

Current Value

$3M

Current Shares

54,488

Total Value Change

+$1.4M

Total Shares Change

+21,785

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Decreased
54,488
-1.8%
$3M0.0%$54.54
0
2026-Q1
Increased
55,506
+1.6%
$2.6M0.0%$47.57
27
2025-Q4
Increased
54,636
+0.8%
$2.9M0.0%$52.44
26
2025-Q3
Decreased
54,220
-6.1%
$3.5M0.0%$64.81
0
2025-Q2
Increased
57,760
+13.4%
$2.8M0.0%$48.64
30
2025-Q1
Increased
50,915
+13.0%
$1.7M0.0%$34.03
29
2024-Q4
Increased
45,062
+37.8%
$1.8M0.0%$39.36
34
2024-Q3
Increased
32,703
+136x
$1.5M0.0%$46.98
41

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used